Literature DB >> 20716765

Phosphatidylinositol 3-kinase signaling in thymocytes: the need for stringent control.

Elisabeth Fayard1, Gerald Moncayo, Brian A Hemmings, Georg A Holländer.   

Abstract

The thymus serves as the primary site for the lifelong formation of new T lymphocytes; hence, it is essential for the maintenance of an effective immune system. Although thymocyte development has been widely studied, the mechanisms involved are incompletely defined. A comprehensive understanding of the molecular events that control regular thymocyte development will not only shed light on the physiological control of T cell differentiation but also probably provide insight into the pathophysiology of T cell immunodeficiencies, the molecular basis that underpins autoimmunity, and the mechanisms that instigate the formation of T cell lymphomas. Phosphatidylinositol 3-kinases (PI3Ks) play a critical role in thymocyte development, although not all of their downstream mediators have yet been identified. Here, we discuss experimental evidence that argues for a critical role of the PI3K-phosphoinositide-dependent protein kinase (PDK1)-protein kinase B (PKB) signaling pathway in the development of both normal and malignant thymocytes, and we highlight molecules that can potentially be targeted therapeutically.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20716765     DOI: 10.1126/scisignal.3135re5

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  21 in total

Review 1.  Transcription factors and target genes of pre-TCR signaling.

Authors:  Cristina López-Rodríguez; Jose Aramburu; Rosa Berga-Bolaños
Journal:  Cell Mol Life Sci       Date:  2015-02-22       Impact factor: 9.261

Review 2.  PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.

Authors:  Lomon So; David A Fruman
Journal:  Biochem J       Date:  2012-03-15       Impact factor: 3.857

Review 3.  Animal models in autoimmune diseases: lessons learned from mouse models for Sjögren's syndrome.

Authors:  Byung Ha Lee; Adrienne E Gauna; Kaleb M Pauley; Yun-Jong Park; Seunghee Cha
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

4.  The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis.

Authors:  Jorge Henao-Mejia; Adam Williams; Loyal A Goff; Matthew Staron; Paula Licona-Limón; Susan M Kaech; Maki Nakayama; John L Rinn; Richard A Flavell
Journal:  Immunity       Date:  2013-04-25       Impact factor: 31.745

Review 5.  Mouse Models of Primary Sjogren's Syndrome.

Authors:  Young-Seok Park; Adrienne E Gauna; Seunghee Cha
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 6.  The perception and response of T cells to a changing environment are based on the law of initial value.

Authors:  Eric S Huseby; Emma Teixeiro
Journal:  Sci Signal       Date:  2022-05-31       Impact factor: 9.517

7.  Transition from heterotypic to homotypic PDK1 homodimerization is essential for TCR-mediated NF-κB activation.

Authors:  Jung-Ah Kang; Sang Phil Jeong; Daeho Park; Matthew S Hayden; Sankar Ghosh; Sung-Gyoo Park
Journal:  J Immunol       Date:  2013-03-25       Impact factor: 5.422

Review 8.  Signal transduction via the T cell antigen receptor in naïve and effector/memory T cells.

Authors:  Arun Kannan; Weishan Huang; Fei Huang; Avery August
Journal:  Int J Biochem Cell Biol       Date:  2012-09-04       Impact factor: 5.085

9.  The novel therapeutic effect of phosphoinositide 3-kinase-γ inhibitor AS605240 in autoimmune diabetes.

Authors:  Jamil Azzi; Robert F Moore; Wassim Elyaman; Marwan Mounayar; Najib El Haddad; Sunmi Yang; Mollie Jurewicz; Ayumi Takakura; Alessandra Petrelli; Paolo Fiorina; Thomas Ruckle; Reza Abdi
Journal:  Diabetes       Date:  2012-03-08       Impact factor: 9.461

10.  PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.

Authors:  Annalisa Lonetti; Alessandra Cappellini; Antonino Maria Spartà; Francesca Chiarini; Francesca Buontempo; Camilla Evangelisti; Cecilia Evangelisti; Ester Orsini; James A McCubrey; Alberto Maria Martelli
Journal:  Oncotarget       Date:  2015-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.